Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nu-3 Gel for Infected Diabetic Foot Ulcers
NCT06020235Phase 2Not yet recruiting
- Sponsor
- Lakewood-Amedex Biotherapeutics
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of bisphosphocin nu-3 in diabetic foot ulcer (DFU) (5 arms), sponsored by Lakewood-Amedex Biotherapeutics. Primary endpoints: Safety and Antimicrobial Efficacy. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
bisphosphocin nu-3
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT06020235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020235.